



PATENT
Attorney Docket No. 056291-5207

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Alan BARGE) Confirmation No. 5602
 Application No.: 10/534,721)
 International Appln. Filing Date: November 7, 2003) Group Art Unit: *Unassigned*
 For: COMBINATION PRODUCT OF INHIBITOR)
 OF THE SRC FAMILY ON NON-RECEPTOR)
 TYROSINE KINASES AND GEMCITABINE)
 THE TREATMENT OF CANCER) Examiner: *Unassigned*

Commissioner for Patents
 U.S. Patent and Trademark Office
 Customer Window
 Randolph Building
 401 Dulany Street
 Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Laurent Francois Andre Hennequin et al.	10/275,382 November 5, 2002		WO 01/94341 December 13, 2001
Laurent Francois Andre Hennequin et al.	10/344,678 February 14, 2003		WO 02/016352 February 28, 2002
Patrick Ple	10/533,931 May 4, 2005		WO 2004/041829 October 31, 2002

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith.

PLEASE DO NOT PRINT the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: October 20, 2005
By:
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

